MedTrace Logo

Study Of Single Ascending And Multiple Doses Of PF-04447943 In Japanese Subjects.

NCT00959803 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 17

Last updated 2009-12-07

No results posted yet for this study

Summary

This study is designed to investigate the safety, tolerability, and pharmacokinetics of PF-04447943 after single and multiple-dose administration to healthy young adult and elderly Japanese subjects, respectively.

Conditions

  • Healthy

Interventions

DRUG

PF-04447943

3 mg solution, oral single dose.

DRUG

PF-04447943

10 mg solution, oral single dose.

DRUG

PF-04447943

25 mg solution, oral single dose.

DRUG

Placebo

Solution, oral single dose.

DRUG

PF-04447943

25 mg solution, oral twice daily for 7 days.

DRUG

Placebo

Solution, oral twice daily for 7 days.

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-08-31
Primary Completion
2009-11-30
Completion
2009-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00959803 on ClinicalTrials.gov